Parmedics Inc. has described proteinase-activated PAR2 receptor antagonists reported to be useful for the treatment of asthma, cancer, osteoarthritis, migraine, chronic pain, inflammatory and vascular ...
A new editorial paper was published in Oncoscience, titled "PH-binding motifs as a platform for drug design: Lessons from protease-activated receptors; PARs." Science X Daily and the Weekly Email ...
Domain Therapeutics SA has disclosed proteinase-activated receptor 2 (PAR2; F2RL1) antagonists reported to be useful for the treatment of allergy, autoimmune and metabolic diseases, cardiovascular ...